Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Trial Profile

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REMIT-iGL
  • Most Recent Events

    • 18 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 29 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top